Fujiwara Hiroshi, Melenhorst J Joseph, El Ouriaghli Frank, Kajigaya Sachiko, Grube Matthias, Sconocchia Giuseppe, Rezvani Katayoun, Price David A, Hensel Nancy F, Douek Daniel C, Barrett A John
Stem Cell Allotransplant Section, Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland 20892, USA.
Clin Cancer Res. 2005 Jun 15;11(12):4495-503. doi: 10.1158/1078-0432.CCR-04-2363.
The primary granule proteins (PGP) of myeloid cells are a source of multiple antigens with immunotherapeutic potential for myeloid leukemias. Therefore, we developed a method to induce T-cell responses to PGP protein sequences. We found that gene-transfected antigen-presenting cells efficiently expand functionally competent PGP-specific CD4 and CD8 T cells. The system was optimized using T-cell responses to autologous CD40-activated B cells (CD40-B) transfected with a cytomegalovirus pp65-encoding expression vector. To generate leukemia-specific T cells, expression vectors encoding the PGP proteinase 3 (PR3), human neutrophil elastase, and cathepsin-G were transfected into CD40-B cells to stimulate post-allogeneic stem cell transplantation T cells from five patients with myeloid and three with lymphoid leukemias. T-cell responses to PGP proteinase 3 and human neutrophil elastase were observed in CD8+ and CD4+ T cells only in patients with myeloid leukemias. T-cell responses against cathepsin-G occurred in both myeloid and lymphoblastic leukemias. T cells from a patient with chronic myelogenous leukemia (CML) and from a posttransplant CML patient, expanded against PGP, produced IFN-gamma or were cytotoxic to the patient's CML cells, demonstrating specific antileukemic efficacy. This study emphasizes the clinical potential of PGP for expansion and adoptive transfer of polyclonal leukemia antigen-specific T cells to treat leukemia.
髓系细胞的初级颗粒蛋白(PGP)是多种具有免疫治疗潜力的抗原来源,可用于治疗髓系白血病。因此,我们开发了一种诱导T细胞对PGP蛋白序列产生反应的方法。我们发现基因转染的抗原呈递细胞能有效扩增功能健全的PGP特异性CD4和CD8 T细胞。该系统通过T细胞对用编码巨细胞病毒pp65的表达载体转染的自体CD40激活B细胞(CD40-B)的反应进行优化。为了产生白血病特异性T细胞,将编码PGP蛋白酶3(PR3)、人中性粒细胞弹性蛋白酶和组织蛋白酶G的表达载体转染到CD40-B细胞中,以刺激来自5例髓系白血病患者和3例淋巴细胞白血病患者的异基因干细胞移植后T细胞。仅在髓系白血病患者的CD8 +和CD4 + T细胞中观察到对PGP蛋白酶3和人中性粒细胞弹性蛋白酶的T细胞反应。在髓系白血病和淋巴细胞白血病中均出现了针对组织蛋白酶G的T细胞反应。来自一名慢性粒细胞白血病(CML)患者和一名移植后CML患者的T细胞,针对PGP进行扩增,产生γ干扰素或对患者的CML细胞具有细胞毒性,证明了其特异性抗白血病疗效。这项研究强调了PGP在扩增和过继转移多克隆白血病抗原特异性T细胞以治疗白血病方面的临床潜力。